Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
The Australian medical community has been put on high alert following a warning issued by the nation’s regulator, the Therapeutic Goods Administration (TGA), regarding a potentially debilitating side effect associated with a popular class of diabetes medications. GLP-1 receptor agonists, which include top-selling drugs like Ozempic, have been linked to a rare but severe eye disorder that can lead to permanent vision loss. According to the TGA, the condition, known as diabetic retinal oedema, can cause fluid to accumulate in the retina, leading to swelling and, in extreme cases, permanent damage to the optic nerve.
While the TGA emphasizes that the risk of developing this condition is relatively low, the regulator is urging healthcare professionals and patients to remain vigilant, particularly those with a history of diabetic retinopathy or other eye problems. The warning comes after an analysis of adverse event reports submitted to the TGA, which revealed a small but significant number of cases involving GLP-1 receptor agonists and vision problems. As a result, the TGA is advising doctors to carefully monitor patients taking these medications for any signs of eye trouble, including blurred vision, floaters, or eye pain, and to refer them to an ophthalmologist if necessary.
The TGA’s warning has significant implications for the thousands of Australians who rely on GLP-1 receptor agonists to manage their type 2 diabetes. While these medications have been shown to be highly effective in controlling blood sugar levels and promoting weight loss, the potential risk of eye damage highlights the need for careful patient monitoring and education. As the TGA continues to investigate this issue, patients taking Ozempic or other GLP-1 receptor agonists are advised to discuss any concerns they may have with their healthcare provider and to report any unusual vision changes immediately. By taking a proactive approach, healthcare professionals and patients can work together to minimize the risks associated with these medications and ensure the best possible outcomes.